Supernus Pharmaceuticals, Inc. (SUPN)

Check out top investors' recommendation for SUPN
Last closing price (N/A)
(0.00%) ? 
Last closing price is the stock price upon last market close (date specified in parenthesis).
Return to date (1m/3m/6m/12m):
N/A ? 
Return to date is the stock return for the specified period of time.
Consensus price target (1m/3m/6m/12m):
59.50
 ? 
Consensus price target is the average analyst price target for a specified period of time.
Buy/Sell Mix (1m/3m/6m/12m):
100%/0%
 ? 
Buy/sell mix the percentage mix between Buy and Sell recommendations for a given company or a research firm. Hold recommendations are excluded.
Description:
Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing products for the treatment of central nervous system diseases. Its products include SPN-538, an extended release topiramate product that completed clinical trials in support of new drug application for the treatment of epilepsy; Epliga, an extended release oxcarbazepine, which is in Phase III clinical trials targeting epilepsy; SPN-810, a molindone hydrochloride that is in Phase II clinical trials for treatment for impulsive aggression in patients with attention deficit hyperactivity disorder; and SPN-812, a Phase II clinical trial product targeting attention deficit hyperactivity disorder. The company also develops SPN-809, which has an open investigational new drug application for the treatment of depression. It intends to market its products to specialty physicians, including neurologists and psychiatrists in the United States. The company was founded in 2005 and is based in Rockville, Maryland.
Sector:
Industry:
Analyst
An analyst is a professional research analyst or an Investor Wand user who issued a recommendation for a given company.
Research Firm
A Research Firm is a company that researches and rates stocks and publishes recommendations.
Signal
Signal is a recommendation issued by an analyst. Investor Wand considers two types of recommendations: BUY and SELL.
Signal Date
A signal date is a date when a BUY or SELL recommendation was issued for given security.
Initial Price
Initial Price is the first closing price for a specified company upon recommendation release. If the recommendation is issued in after-market hours, the Initial Price is the next day’s closing price (for a given symbol). In case of dividend distributions and stock splits, Initial Price is adjusted.
Price Target
A Price Target is an analyst’s projection of a company’s stock price by the end of the recommendation period. It represents the price at which the analyst would exit his or her existing position.
Closing Date
Closing Date is the expiration date of a recommendation. The validity timeframe of a professional analyst’s recommendation is 12 months. Investor Wand analysts can set their recommendation timeframe to one, three, six, or 12 months.
Return
The return on a single open recommendation is calculated as the maximum of the current return (based on the latest closing price) and the target price return, if the symbol reached the target. The return on a single closed recommendation is calculated as the maximum of the return on the closing date (at the end of recommendation timeframe) and the target price return, if the stock hit the target price. The return is adjusted for one-time events (e.g., stock splits).
William Tanner Lazard Capital Markets Buy   Sep 13, '18     56.00  Sep 13, '19  N/A 
David Steinberg Deutsche Bank Securities Buy   Aug 09, '18     58.00  Aug 09, '19  N/A 
William Tanner Lazard Capital Markets Buy   Aug 08, '18     56.00  Aug 08, '19  N/A 
David Buck Shore Capital Buy   Jun 25, '18     68.00  Jun 25, '19  N/A 
Annabel Samimy Stifel Nicolaus & Company, Inc. Buy   May 25, '18     60.00  May 25, '19  N/A 
William Tanner Lazard Capital Markets Buy   Feb 28, '18     52.00  Feb 28, '19  N/A 
David Buck Shore Capital Buy   Feb 26, '18     54.00  Feb 26, '19  N/A 
Annabel Samimy Stifel Nicolaus & Company, Inc. Buy   Jan 02, '18     48.00  Jan 02, '19  N/A 
David Buck Shore Capital Buy   Dec 28, '17     54.00  Dec 28, '18  N/A 
Ken Trbovich C.K. Cooper & Company Buy   Dec 04, '17     47.00  Dec 04, '18  N/A 
David Buck Shore Capital Buy   Nov 20, '17     50.00  Nov 20, '18  N/A 
Annabel Samimy Stifel Nicolaus & Company, Inc. Buy   Nov 08, '17     47.00  Nov 08, '18  N/A 
William Tanner Lazard Capital Markets Buy   Nov 06, '17     50.00  Nov 06, '18  N/A 
Ken Cacciatore Cowen And Company Buy   Oct 23, '17     50.00  Oct 23, '18  N/A 
David Buck Shore Capital Buy   Oct 18, '17     53.00  Oct 18, '18  N/A 
David Steinberg Deutsche Bank Securities Buy   Sep 20, '17     51.00  Sep 20, '18  N/A 
William Tanner Lazard Capital Markets Buy   Sep 18, '17     49.00  Sep 18, '18  N/A 
Annabel Samimy Stifel Nicolaus & Company, Inc. Buy   Sep 01, '17     47.00  Sep 01, '18  N/A 
David Steinberg Deutsche Bank Securities Buy   Aug 03, '17     51.00  Aug 03, '18  N/A 
Ken Cacciatore Cowen And Company Buy   Aug 03, '17     50.00  Aug 03, '18  N/A 
< previous12